{"id":6467,"date":"2019-11-19T21:29:56","date_gmt":"2019-11-19T15:59:56","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6467"},"modified":"2021-07-24T12:57:38","modified_gmt":"2021-07-24T07:27:38","slug":"recent-pharma-happenings-for-nordisk-dicerna-pfizer-rodin-alkermes","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-nordisk-dicerna-pfizer-rodin-alkermes","title":{"rendered":"Nordisk ties up with Dicerna; Pfizer’s drug gets FDA nod"},"content":{"rendered":"\n

Novo Nordisk has announced to enter into a collaboration with\nDicerna\u2019s RNAi platform to focus on metabolic and liver-related diseases. <\/strong><\/h2>\n\n\n\n

The companies will be focusing to advance the treatment landscape of the diseases such as non-alcoholic steatohepatitis (NASH), Type 2 diabetes and obesity. Nordisk will be investing an amount of USD 225 Million upfront along with hundreds of millions up to USD 357.5 million upon achieving the regulatory and commercialization milestones and targets. However, Dicerna will be funding the initial pre-clinical development phases of the products. Furthermore, Nordisk will be investing USD 50 million in Dicerna\u2019s equity. \u00a0<\/p>\n\n\n\n

After the announcement of the deal, Dicerna observed an 18%\nrise in its stocks. <\/p>\n\n\n\n

The companies are planning to use Dicerna\u2019s GalXC technology for discovering and developing new treatments for liver diseases. Moreover, the collaboration will work on more than 30 liver cell targets. <\/p>\n\n\n\n

Dicerna will fund and carry out discovery and preclinical\nwork through candidate selection for each target, after which Novo will take\nover development, the duo said in a statement.<\/p>\n\n\n\n

Pfizer has received the green light from the US FDA for its drug, Abrilada (adalimumab-afzb), a biosimilar for<\/strong> AbbVie\u2019s Humira. <\/strong><\/h2>\n\n\n\n

Abrilada has received the recommendations from the FDA for the treatment of rheumatoid arthritis<\/a>, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis. <\/p>\n\n\n\n

Abrilada, the fifth biosimilar to Humira, is a tumour necrosis factor (TNF). <\/p>\n\n\n\n

The approval from the FDA came after results of trials REFLECTIONS B538-02. The drug was evaluated on the basis of its efficacy, safety, or immunogenicity and compared with the reference product Humira in patients with rheumatoid arthritis. The biosimilar was given in combination therapy with the methotrexate. <\/p>\n\n\n\n

At present, there is no standard cure for the disease. The rheumatoid arthritis therapy goals are mainly to alleviate pain, control inflammation, preserve the ability of the patient to function in activities of daily living and work and avert joint destruction.<\/p>\n\n\n\n

However, rheumatoid arthritis treatment<\/a> landscape has advanced markedly over the last two decade. <\/p>\n\n\n\n

Alkermes, an Irish biopharma company, has announced the\npurchase of Rodin Therapeutics, in a deal worth USD 950 Million. <\/strong><\/h2>\n\n\n\n

Under the terms of the agreement, Alkermes will be paying a\ntotal of USD 100 Million upfront cash and around USD 850 Million upon achieving\nclinical and regulatory milestones. <\/p>\n\n\n\n

Rodin Therapeutics is a neuroscience firm that develops treatments for synaptopathies. The company manufactures first-in-class, orally-administered molecules that easily permeates through the brain. These target specific histone deacetylase (HDAC) complexes.<\/p>\n\n\n\n

Synaptic dysfunction in the brain is a result of disturbances\nin the physiological synapse structure affecting its normal functioning. <\/p>\n","protected":false},"excerpt":{"rendered":"

Novo Nordisk has announced to enter into a collaboration with Dicerna\u2019s RNAi platform to focus on metabolic and liver-related diseases. The companies will be focusing to advance the treatment landscape of the diseases such as non-alcoholic steatohepatitis (NASH), Type 2 diabetes and obesity. Nordisk will be investing an amount of USD 225 Million upfront along […]<\/p>\n","protected":false},"author":1,"featured_media":6468,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17817,17820,1616,17819,349,877,460,712,639,17818],"industry":[17225],"therapeutic_areas":[17240,17239],"class_list":["post-6467","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbvies-humira","tag-abrilada","tag-alkermes","tag-dicerna","tag-latest-pharma-news","tag-novo-nordisk","tag-pfizer","tag-pharma-industry","tag-pharma-news","tag-rodin-therapeutics","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-gastroenterology"],"acf":[],"yoast_head":"\nNordisk ties up with Dicerna; Pfizer's drug gets FDA nod<\/title>\n<meta name=\"description\" content=\"Pfizer has received the green light from the US FDA for its drug, Abrilada (adalimumab-afzb), a biosimilar for AbbVie\u2019s Humira.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-nordisk-dicerna-pfizer-rodin-alkermes\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nordisk ties up with Dicerna; Pfizer's drug gets FDA nod\" \/>\n<meta property=\"og:description\" content=\"Pfizer has received the green light from the US FDA for its drug, Abrilada (adalimumab-afzb), a biosimilar for AbbVie\u2019s Humira.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-nordisk-dicerna-pfizer-rodin-alkermes\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-19T15:59:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/04171317\/Pharma-news-19-Nov.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nordisk ties up with Dicerna; Pfizer's drug gets FDA nod","description":"Pfizer has received the green light from the US FDA for its drug, Abrilada (adalimumab-afzb), a biosimilar for AbbVie\u2019s Humira.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-nordisk-dicerna-pfizer-rodin-alkermes","og_locale":"en_US","og_type":"article","og_title":"Nordisk ties up with Dicerna; Pfizer's drug gets FDA nod","og_description":"Pfizer has received the green light from the US FDA for its drug, Abrilada (adalimumab-afzb), a biosimilar for AbbVie\u2019s Humira.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-nordisk-dicerna-pfizer-rodin-alkermes","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-11-19T15:59:56+00:00","article_modified_time":"2021-07-24T07:27:38+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/04171317\/Pharma-news-19-Nov.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-nordisk-dicerna-pfizer-rodin-alkermes","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-nordisk-dicerna-pfizer-rodin-alkermes","name":"Nordisk ties up with Dicerna; Pfizer's drug gets FDA nod","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-nordisk-dicerna-pfizer-rodin-alkermes#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-nordisk-dicerna-pfizer-rodin-alkermes#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/04171317\/Pharma-news-19-Nov.png","datePublished":"2019-11-19T15:59:56+00:00","dateModified":"2021-07-24T07:27:38+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Pfizer has received the green light from the US FDA for its drug, Abrilada (adalimumab-afzb), a biosimilar for AbbVie\u2019s Humira.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-nordisk-dicerna-pfizer-rodin-alkermes"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-nordisk-dicerna-pfizer-rodin-alkermes#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/04171317\/Pharma-news-19-Nov.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/04171317\/Pharma-news-19-Nov.png","width":772,"height":482,"caption":"Pharma news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/04171317\/Pharma-news-19-Nov-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AbbVie\u0092s Humira<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Abrilada<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alkermes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dicerna<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novo Nordisk<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rodin Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie\u0092s Humira<\/span>","<span class=\"advgb-post-tax-term\">Abrilada<\/span>","<span class=\"advgb-post-tax-term\">Alkermes<\/span>","<span class=\"advgb-post-tax-term\">Dicerna<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Rodin Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 19, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 19, 2019 9:29 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6467"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6467\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6468"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6467"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6467"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}